RESEARCH
CATALOG

Sustained-release combination of T4 (levothyroxine) and T3 (liothyronine) at 120 mcg and 30 mcg per tablet in a 4:1 ratio. Formulated as a research alternative to Cynoplus, which supplies a 5:1 ratio in immediate-release form. HPMC slow-release matrix extends T3 release over 4-8 hours. Used in research on combination thyroid protocols and sustained T3 availability.

Levothyroxine sodium (T4) at 100 mcg per tablet, 50 tablets per bottle. Used in research on thyroid hormone replacement models, peripheral T4 to T3 conversion, and deiodinase pathway activity. Pharmacy-grade purity.

Slow-release methylated B-vitamin complex modeled on the Igennus Super B-Complex formulation. All eight B vitamins delivered in their active or bioidentical forms - folate as L-5-MTHF (not folic acid), B12 as methylcobalamin (not cyanocobalamin), B6 as pyridoxal-5-phosphate. Sustained-release matrix extends absorption over 4-6 hours. 60 tablets per bottle. Pharmacy-grade purity, USP/EP-compliant raw materials.

First-generation antihistamine with combined H1 receptor and 5-HT2 serotonin receptor antagonism. Used in research on MCAS-related histamine signaling, appetite-stimulant pathways, migraine prophylaxis mechanisms, and serotonin-syndrome reversal. 4 mg per tablet, 50 tablets per bottle. Pharmacy-grade purity.

Sustained-release combination of T3 (liothyronine) and 3,5-T2 (3,5-diiodo-L-thyronine) at 15 mcg each in a 1:1 ratio per capsule. HPMC slow-release matrix extends release over 4-8 hours. Used in research on T3-protocol plateau correction, mitochondrial co-activation, and the T3->T2 conversion bottleneck.

Sustained-release combination of T3 (liothyronine) and 3,5-T2 (3,5-diiodo-L-thyronine) at 45 mcg each in a 1:1 ratio per capsule. HPMC slow-release matrix extends release over 4-8 hours. Used in research on T3-protocol plateau correction, mitochondrial co-activation, and the T3->T2 conversion bottleneck.

Sustained-release combination of T3 (liothyronine) and 3,5-T2 (3,5-diiodo-L-thyronine) at 7.5 mcg each in a 1:1 ratio per capsule. HPMC slow-release matrix extends release over 4-8 hours. Used in research on T3-protocol plateau correction, mitochondrial co-activation, and the T3->T2 conversion bottleneck.

The complete Wilson's Temperature Syndrome T3+T2 protocol kit. Includes 1x SRT3+T2-7.5, 1x SRT3+T2-15, 1x SRT3+T2-22.5, and 1x SRT3+T2-45. Each capsule contains T3 and 3,5-T2 in a 1:1 mcg ratio. Designed for cyclic titration protocols that address both the T4->T3 conversion problem (via the T3 component) and the often-overlooked T3->T2 conversion problem (via the T2 component).

Sustained-release combination of T3 (liothyronine) and 3,5-T2 (3,5-diiodo-L-thyronine) at 90 mcg each in a 1:1 ratio per capsule. HPMC slow-release matrix extends release over 4-8 hours. Used in research on T3-protocol plateau correction, mitochondrial co-activation, and the T3->T2 conversion bottleneck.

Sustained-release combination of T3 (liothyronine) and 3,5-T2 (3,5-diiodo-L-thyronine) at 22.5 mcg each in a 1:1 ratio per capsule. HPMC slow-release matrix extends release over 4-8 hours. Used in research on T3-protocol plateau correction, mitochondrial co-activation, and the T3->T2 conversion bottleneck.

Ivermectin (12mg tablets, 50 count), an avermectin-class macrocyclic lactone used in research on antiparasitic mechanisms, antiviral pathways, and anti-inflammatory signaling.

Complete slow-release T3 kit for Wilson's Temperature Syndrome research protocols. Includes 1x SRT3-7.5, 1x SRT3-15, 1x SRT3-22.5, and 1x SRT3-45. Bundled to support multi-dose research designs that may require extended cycle lengths.

Slow-release T3 (90mcg, 50 tablets) - highest-strength formulation, used in research on sustained T3 availability and Wilson's Temperature Syndrome protocols.

WL-1, an HSV-1-focused antiviral peptide used in research on immune defense and viral suppression pathways.

Slow-release T3 (45mcg, 50 tablets), used in research on sustained T3 availability and Wilson's Temperature Syndrome protocols.

Slow-release T3 (22.5mcg, 50 tablets), used in research on sustained T3 availability and Wilson's Temperature Syndrome protocols.

Slow-release T3 (15mcg, 50 tablets), used in research on sustained T3 availability and Wilson's Temperature Syndrome protocols.

Slow-release T3 (7.5mcg, 50 tablets), used in research on sustained T3 availability and Wilson's Temperature Syndrome protocols.